Range Cancer Therapeutics ETF (CNCR) Short Interest Ratio & Short Volume → This military-backed stock “owns” AI market (From Porter & Company) (Ad) Free CNCR Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Short InterestStock AnalysisDividendHeadlinesHoldingsRatingsShort InterestTrendsStock AnalysisDividendHeadlinesHoldingsRatingsShort InterestTrends Range Cancer Therapeutics ETF Short Interest DataCurrent Short Interest24,600 sharesPrevious Short Interest2,900 sharesChange Vs. Previous Month+748.28%Dollar Volume Sold Short$374,904.00Short Interest Ratio0.7 Days to CoverLast Record DateMay 15, 2024Outstanding Shares1,180,000 sharesPercentage of Shares Shorted2.08%Today's Trading Volume6,875 sharesAverage Trading Volume6,668 sharesToday's Volume Vs. Average103% Short Selling Range Cancer Therapeutics ETF ? Sign up to receive the latest short interest report for Range Cancer Therapeutics ETF and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartCNCR Short Interest Over TimeCNCR Days to Cover Over TimeCNCR Percentage of Float Shorted Over Time Ad Porter & CompanyThis military-backed stock “owns” AI marketThe AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. Range Cancer Therapeutics ETF Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/202424,600 shares $374,904.00 +748.3%N/A0.7 $15.24 4/30/20242,900 shares $42,804.00 -79.1%N/A0.1 $14.76 4/15/202413,900 shares $208,639.00 -50.2%N/A0.4 $15.01 3/31/202427,900 shares $463,698.00 -59.2%N/A0.8 $16.62 3/15/202468,300 shares $1.11 million +73.4%N/A2.1 $16.26 2/29/202439,400 shares $680,438.00 +47.0%N/A2.6 $17.27 Get the Latest News and Ratings for CNCR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Range Cancer Therapeutics ETF and its competitors with MarketBeat's FREE daily newsletter. 2/15/202426,800 shares $429,738.00 +538.1%N/A2.9 $16.04 1/31/20244,200 shares $59,472.00 No ChangeN/A0.8 $14.16 5/15/2023100 shares $1,374.00 -92.9%N/A0 $13.74 4/30/20231,400 shares $17,707.90 -44.0%N/A0.2 $12.65 4/15/20232,500 shares $31,025.00 +257.1%N/A0.4 $12.41 3/31/2023700 shares $8,393.00 +16.7%N/A0.1 $11.99 3/15/2023600 shares $7,494.00 -78.6%N/A0.2 $12.49 2/28/20232,800 shares $37,660.00 -47.2%N/A0.8 $13.45 2/15/20235,300 shares $75,366.00 -38.4%N/A1.5 $14.22 1/31/20238,600 shares $127,710.00 -4.4%N/A2.5 $14.85 1/15/20239,000 shares $132,750.00 +5.9%N/A1.4 $14.75 12/30/20228,500 shares $116,705.00 -35.6%N/A1.3 $13.73 12/15/202213,200 shares $200,376.00 +12.8%N/A1.4 $15.18 11/30/202211,700 shares $174,447.00 +9.4%N/A1.3 $14.91 11/15/202210,700 shares $165,743.00 -23.0%N/A1.2 $15.49 10/31/202213,900 shares $208,500.00 +0.7%N/A1.5 $15.00 10/15/202213,800 shares $201,894.00 No ChangeN/A2.1 $14.63 9/30/202212,700 shares $183,134.00 -21.1%N/A1.7 $14.42 9/15/202216,100 shares $260,820.00 +3.9%N/A3 $16.20 8/31/202215,500 shares $240,405.00 -15.8%N/A2.2 $15.51 8/15/202218,400 shares $330,832.00 +13.6%N/A2.5 $17.98 7/31/202216,200 shares $259,200.00 -12.0%N/A2.1 $16.00 7/15/202218,400 shares $304,704.00 -27.0%N/A2.4 $16.56 6/30/202225,200 shares $382,788.00 -2.0%N/A3.8 $15.19 6/15/202225,700 shares $345,022.50 +26.0%N/A3.7 $13.43 5/31/202220,400 shares $283,941.48 +23.6%N/A3.9 $13.92 5/15/202216,500 shares $236,445.00 +17.0%N/A3.4 $14.33 4/30/202214,100 shares $218,225.70 -6.0%N/A3.1 $15.48 4/15/202215,000 shares $264,150.00 -8.5%N/A2.1 $17.61 3/31/202216,400 shares $297,332.00 -13.7%N/A1.9 $18.13 3/15/202219,000 shares $311,790.00 +36.7%N/A2.3 $16.41 2/28/202213,900 shares $255,760.00 -30.5%N/A1.6 $18.40 2/15/202220,000 shares $372,020.00 +48.2%N/A2.2 $18.60 1/31/202213,500 shares $247,847.85 +5.5%N/A1.5 $18.36Trump’s Gift Could Unleash $51 Billion in New Wealth (Ad)In January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”.You just have to make this simple move before July 30, 2024. 1/15/202212,800 shares $261,120.00 +1,728.6%N/A1.9 $20.40 12/31/2021700 shares $17,037.30 -50.0%N/A0.1 $24.34 12/15/20211,400 shares $34,716.36 -6.7%N/A0.3 $24.80 11/30/20211,500 shares $40,320.00 +150.0%N/A0.3 $26.88 11/15/2021600 shares $17,136.00 -14.3%N/A0.1 $28.56 10/29/2021700 shares $20,189.19 +16.7%N/A0.1 $28.84 10/15/2021600 shares $17,514.00 -33.3%N/A0.1 $29.19 9/30/2021900 shares $27,837.00 +50.0%N/A0.2 $30.93 9/15/2021600 shares $18,552.00 No ChangeN/A0.1 $30.92 8/31/2021600 shares $18,336.00 -64.7%N/A0.1 $30.56 8/13/20211,700 shares $48,909.00 No ChangeN/A0.3 $28.77 7/30/20211,700 shares $50,405.00 -48.5%N/A0.3 $29.65 7/15/20213,300 shares $97,350.00 -2.9%N/A0.6 $29.50 6/30/20213,400 shares $108,426.00 +13.3%N/A0.5 $31.89 6/15/20213,000 shares $91,860.00 +11.1%N/A0.4 $30.62 5/28/20212,700 shares $82,593.00 +28.6%N/A0.4 $30.59 5/14/20212,100 shares $60,480.00 +10.5%N/A0.3 $28.80 4/30/20211,900 shares $58,862.00 -74.7%N/A0.3 $30.98 4/15/20217,500 shares $218,250.00 +17.2%N/A1 $29.10 3/31/20216,400 shares $185,920.00 +25.5%N/A0.8 $29.05 3/15/20215,100 shares $163,149.00 No ChangeN/A0.6 $31.99 2/26/20215,100 shares $159,120.00 -60.8%N/A0.5 $31.20 2/12/202113,000 shares $449,686.90 +3.2%N/A1.2 $34.59 1/29/202112,600 shares $411,982.20 +215.0%N/A1.2 $32.70 1/15/20214,000 shares $139,985.20 No ChangeN/A0.4 $35.00 CNCR Short Interest - Frequently Asked Questions What is Range Cancer Therapeutics ETF's current short interest? Short interest is the volume of Range Cancer Therapeutics ETF shares that have been sold short but have not yet been covered or closed out. As of May 15th, investors have sold 24,600 shares of CNCR short. Learn More on Range Cancer Therapeutics ETF's current short interest. What is a good short interest ratio for Range Cancer Therapeutics ETF? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CNCR shares currently have a short interest ratio of 1.0. Learn More on Range Cancer Therapeutics ETF's short interest ratio. Is Range Cancer Therapeutics ETF's short interest increasing or decreasing? Range Cancer Therapeutics ETF saw a increase in short interest in May. As of May 15th, there was short interest totaling 24,600 shares, an increase of 748.3% from the previous total of 2,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Range Cancer Therapeutics ETF's short interest compare to its competitors? Here is how the short interest of companies compare to Range Cancer Therapeutics ETF: First Trust Nasdaq Pharmaceuticals ETF (0.13%), JPMorgan Healthcare Leaders ETF (0.08%), ProShares UltraShort Nasdaq Biotechnology (7.41%), Invesco Nasdaq Biotechnology ETF (0.71%), Principal Healthcare Innovators ETF (0.12%), ProShares Ultra Nasdaq Biotechnology (0.74%), Invesco S&P SmallCap Health Care ETF (0.03%), VanEck Biotech ETF (0.11%), VanEck Pharmaceutical ETF (19.53%), and iShares Biotechnology ETF (16.73%). Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks. What does it mean to sell short Range Cancer Therapeutics ETF stock? Short selling CNCR is an investing strategy that aims to generate trading profit from Range Cancer Therapeutics ETF as its price is falling. CNCR shares are trading down $0.08 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Range Cancer Therapeutics ETF? A short squeeze for Range Cancer Therapeutics ETF occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CNCR, which in turn drives the price of the stock up even further. How often is Range Cancer Therapeutics ETF's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CNCR, twice per month. The most recent reporting period available is May, 15 2024. More Short Interest Resources from MarketBeat Related Companies: First Trust Nasdaq Pharmaceuticals ETF Short Interest Data JPMorgan Healthcare Leaders ETF Short Interest Data ProShares UltraShort Nasdaq Biotechnology Short Interest Data Invesco Nasdaq Biotechnology ETF Short Interest Data Principal Healthcare Innovators ETF Short Interest Data ProShares Ultra Nasdaq Biotechnology Short Interest Data Invesco S&P SmallCap Health Care ETF Short Interest Data VanEck Biotech ETF Short Interest Data VanEck Pharmaceutical ETF Short Interest Data iShares Biotechnology ETF Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CNCR) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsThe only AI company to buyPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Range Cancer Therapeutics ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.